Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update of ViPOR-P (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in combination with polatuzumab for relapsed/refractory B-cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Deltasone (prednisone)
• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)
• Polivy (polatuzumab vedotin)
• Revlimid (lenalidomide)
• Venclexta (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING